Cannabis Stock Destroyed by 81% Decline on Clinical Trial Failure

Cannabis Stock Destroyed by 81% Decline on Clinical Trial Failure


Intec Pharma Ltd. is a tiny company in the space of pot stocks, doing clinical research involving cannabis. But one of their drugs failed a Stage III clinical trial. Intec’s stock got crushed and lost 81 percent of its value. Death of A Cannabis Stock Dream Intec has three drugs in its pipeline, including cannabis […]

The post Cannabis Stock Destroyed by 81% Decline on Clinical Trial Failure appeared first on CCN Markets

Posted by Lawrence Meyers on July 23, 2019 @ https://www.ccn.com/news/cannabis-stock-destroyed-by-81-decline-on-clinical-trial-failure/2019/07/22/

Comments are closed.